UnitedHealth Group Incorporated

The forensic scores on file are limited. The Beneish M-Score, Altman Z-Score, Piotroski F-Score and Fog Index are not on file for this company, so this synthesis gives no values for them. The one quality measure provided is the ratio of operating cash flow to net income for 2024, which is 1.68, meaning operating cash flow of $24.2 billion against net income of $14.4 billion. No label is attached to this ratio in the data, so it should be read as a plain ratio rather than a screening result. Its meaning depends on context: net income fell from $22.38 billion in 2023 to $14.4 billion in 2024, a drop of about 36%, while operating income was nearly flat at $32.29 billion versus $32.36 billion. A ratio above 1 can partly reflect lower reported earnings rather than stronger cash generation, so readers may want to look at how the cash flow and earnings lines move together over several years. The balance sheet also shows growing obligations. Total liabilities were $209.46 billion at September 30, 2025, up from $195.69 billion at December 31, 2024, and long-term debt was $72.40 billion. The market risk table shows that a 1 percentage point rise in rates across the yield curve would add $288 million per year to interest expense and would reduce the fair value of financial assets by $2,170 million and of financial liabilities by $5,160 million. Capital return continued, with nine-month share repurchases of $5.53 billion and dividends of $6.52 per share totaling $5.91 billion. The filing reports no repurchases in the third quarter and 21 million shares remaining under authorization. The regulatory matters the filing names include DOJ legal actions over Medicare participation, CMS star ratings, and risk adjustment data validation audits, all of which bear on government program revenue.

Catalyst.UnitedHealth's 2024 annual revenue rose 7.7% to $400.28 billion, and the 2025 10-Q shows that growth continuing. Total revenues for the nine months ended September 30, 2025 were $334.35 billion, up about 11.6% from $299.47 billion, with premiums reaching $263.42 billion. Third-quarter total revenues were $113.16 billion versus $100.82 billion a year earlier. Management's forward-looking statements list medical cost estimation and pricing first among the factors that could change results, and that cost line is where earnings are being pressed. Nine-month net earnings attributable to common shareholders rose to $12.05 billion from $8.86 billion, but that comparison is flattered by an $8.33 billion loss on sale of subsidiaries recorded in the 2024 period.

Hidden risk.The earnings line that matters most for the core business is earnings from operations, which fell to $18.58 billion for the nine months from $24.51 billion, a decline of about 24%. Medical costs rose to $231.95 billion from $197.15 billion, about 17.6%, faster than premiums at about 13.4%. Medical costs as a share of premiums moved from about 84.9% to about 88.0%. Operating cash flow also fell to $18.59 billion from $21.84 billion, and it was supported by a $6.18 billion increase in medical costs payable, a liability for medical claims not yet paid. Current borrowings and current maturities of long-term debt rose to $7.74 billion from $4.55 billion. The risk factors section states there are no material changes from the 2024 10-K, so readers may want to look at Note 7 on legal proceedings, which is incorporated by reference but is not included in this excerpt.